{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T07:43:49Z","timestamp":1769759029993,"version":"3.49.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,29]]},"DOI":"10.7759\/cureus.102565","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T16:22:53Z","timestamp":1769703773000},"source":"Crossref","is-referenced-by-count":0,"title":["Evaluating the Diagnostic Potential of Myxovirus Resistance Protein 1 (MX1) and Myxovirus Resistance Protein 2 (MX2) As Biomarkers in Idiopathic Inflammatory Myopathies"],"prefix":"10.7759","author":[{"given":"Raghavee","family":"Neupane","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"Haider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Perry","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc M","family":"Kesselman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00321-x","article-title":"Idiopathic inflammatory myopathies","volume":"7","author":"Lundberg IE","year":"2021","unstructured":"Lundberg IE, Fujimoto M, Vencovsky J, et al.. Idiopathic inflammatory myopathies. Nat Rev Dis Primers. 2021, 7:86. 10.1038\/s41572-021-00321-x","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-023-01073-6","article-title":"Metabolic profiling of patients with different idiopathic inflammatory myopathy subtypes reveals potential biomarkers in plasma","volume":"23","author":"Zhao Q","year":"2023","unstructured":"Zhao Q, Hu Q, Meng S, et al.. Metabolic profiling of patients with different idiopathic inflammatory myopathy subtypes reveals potential biomarkers in plasma. Clin Exp Med. 2023, 23:3417-29. 10.1007\/s10238-023-01073-6","journal-title":"Clin Exp Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1146015","article-title":"Imaging biomarkers in the idiopathic inflammatory myopathies","volume":"14","author":"Zubair AS","year":"2023","unstructured":"Zubair AS, Salam S, Dimachkie MM, Machado PM, Roy B. Imaging biomarkers in the idiopathic inflammatory myopathies. Front Neurol. 2023, 14:1146015. 10.3389\/fneur.2023.1146015","journal-title":"Front Neurol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/imj.15358","article-title":"Idiopathic inflammatory myopathies: a review","volume":"51","author":"Ashton C","year":"2021","unstructured":"Ashton C, Paramalingam S, Stevenson B, Brusch A, Needham M. Idiopathic inflammatory myopathies: a review. Intern Med J. 2021, 51:845-52. 10.1111\/imj.15358","journal-title":"Intern Med J"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S197941","article-title":"Statin-associated autoimmune myopathy: current perspectives","volume":"16","author":"Tiniakou E","year":"2020","unstructured":"Tiniakou E. Statin-associated autoimmune myopathy: current perspectives. Ther Clin Risk Manag. 2020, 16:483-92. 10.2147\/TCRM.S197941","journal-title":"Ther Clin Risk Manag"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.4137\/CCRPM.S36748","article-title":"Biomarkers and autoantibodies of interstitial lung disease with idiopathic inflammatory myopathies","volume":"9","author":"Yoshifuji H","year":"2015","unstructured":"Yoshifuji H. Biomarkers and autoantibodies of interstitial lung disease with idiopathic inflammatory myopathies. Clin Med Insights Circ Respir Pulm Med. 2015, 9:141-6. 10.4137\/CCRPM.S36748","journal-title":"Clin Med Insights Circ Respir Pulm Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-023-01033-0","article-title":"Epidemiology of the idiopathic inflammatory myopathies","volume":"19","author":"Khoo T","year":"2023","unstructured":"Khoo T, Lilleker JB, Thong BY, Leclair V, Lamb JA, Chinoy H. Epidemiology of the idiopathic inflammatory myopathies. Nat Rev Rheumatol. 2023, 19:695-712. 10.1038\/s41584-023-01033-0","journal-title":"Nat Rev Rheumatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2117912","article-title":"Trial of intravenous immune globulin in dermatomyositis","volume":"387","author":"Aggarwal R","year":"2022","unstructured":"Aggarwal R, Charles-Schoeman C, Schessl J, et al.. Trial of intravenous immune globulin in dermatomyositis. N Engl J Med. 2022, 387:1264-78. 10.1056\/NEJMoa2117912","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2015.02.007","article-title":"Discovery of new biomarkers of idiopathic inflammatory myopathy","volume":"444","author":"Lu X","year":"2015","unstructured":"Lu X, Peng Q, Wang G. Discovery of new biomarkers of idiopathic inflammatory myopathy. Clin Chim Acta. 2015, 444:117-25. 10.1016\/j.cca.2015.02.007","journal-title":"Clin Chim Acta"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.00554","article-title":"Biomarkers in inflammatory myopathies-an expanded definition","volume":"10","author":"Benveniste O","year":"2019","unstructured":"Benveniste O, Goebel HH, Stenzel W. Biomarkers in inflammatory myopathies-an expanded definition. Front Neurol. 2019, 10:554. 10.3389\/fneur.2019.00554","journal-title":"Front Neurol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.8.4154","article-title":"Gene expression profiling in DQA1*0501+ children with untreated dermatomyositis: a novel model of pathogenesis","volume":"168","author":"Tezak Z","year":"2002","unstructured":"Tezak Z, Hoffman EP, Lutz JL, et al.. Gene expression profiling in DQA1*0501+ children with untreated dermatomyositis: a novel model of pathogenesis. J Immunol. 2002, 168:4154-63. 10.4049\/jimmunol.168.8.4154","journal-title":"J Immunol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20464","article-title":"Interferon-alpha\/beta-mediated innate immune mechanisms in dermatomyositis","volume":"57","author":"Greenberg SA","year":"2005","unstructured":"Greenberg SA, Pinkus JL, Pinkus GS, et al.. Interferon-alpha\/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol. 2005, 57:664-78. 10.1002\/ana.20464","journal-title":"Ann Neurol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21805","article-title":"Interferon-stimulated gene 15 (ISG15) conjugates proteins in dermatomyositis muscle with perifascicular atrophy","volume":"67","author":"Salajegheh M","year":"2010","unstructured":"Salajegheh M, Kong SW, Pinkus JL, et al.. Interferon-stimulated gene 15 (ISG15) conjugates proteins in dermatomyositis muscle with perifascicular atrophy. Ann Neurol. 2010, 67:53-63. 10.1002\/ana.21805","journal-title":"Ann Neurol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31821f440a","article-title":"Type I interferon and Toll-like receptor expression characterizes inflammatory myopathies","volume":"76","author":"Cappelletti C","year":"2011","unstructured":"Cappelletti C, Baggi F, Zolezzi F, et al.. Type I interferon and Toll-like receptor expression characterizes inflammatory myopathies. Neurology. 2011, 76:2079-88. 10.1212\/WNL.0b013e31821f440a","journal-title":"Neurology"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0029161","article-title":"Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases","volume":"7","author":"Wong D","year":"2012","unstructured":"Wong D, Kea B, Pesich R, et al.. Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases. PLoS One. 2012, 7:e29161. 10.1371\/journal.pone.0029161","journal-title":"PLoS One"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.12955","article-title":"The role of interferons type I, II and III in myositis: a review","volume":"31","author":"Bolko L","year":"2021","unstructured":"Bolko L, Jiang W, Tawara N, Landon-Cardinal O, Anquetil C, Benveniste O, Allenbach Y. The role of interferons type I, II and III in myositis: a review. Brain Pathol. 2021, 31:e12955. 10.1111\/bpa.12955","journal-title":"Brain Pathol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103334","article-title":"The interferon in idiopathic inflammatory myopathies: different signatures and new therapeutic perspectives. A literature review","volume":"22","author":"Gasparotto M","year":"2023","unstructured":"Gasparotto M, Franco C, Zanatta E, et al.. The interferon in idiopathic inflammatory myopathies: different signatures and new therapeutic perspectives. A literature review. Autoimmun Rev. 2023, 22:103334. 10.1016\/j.autrev.2023.103334","journal-title":"Autoimmun Rev"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008128","article-title":"Identification of distinctive interferon gene signatures in different types of myositis","volume":"93","author":"Pinal-Fernandez I","year":"2019","unstructured":"Pinal-Fernandez I, Casal-Dominguez M, Derfoul A, et al.. Identification of distinctive interferon gene signatures in different types of myositis. Neurology. 2019, 93:e1193-204. 10.1212\/WNL.0000000000008128","journal-title":"Neurology"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1186\/ar2885","article-title":"Type 1 interferons and myositis","volume":"12 Suppl 1","author":"Greenberg SA","year":"2010","unstructured":"Greenberg SA. Type 1 interferons and myositis. Arthritis Res Ther. 2010, 12 Suppl 1:S4. 10.1186\/ar2885","journal-title":"Arthritis Res Ther"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1169057","article-title":"Type 1 interferon signature in peripheral blood mononuclear cells and monocytes of idiopathic inflammatory myopathy patients with different myositis-specific autoantibodies","volume":"14","author":"Li M","year":"2023","unstructured":"Li M, Zhang Y, Zhang W, et al.. Type 1 interferon signature in peripheral blood mononuclear cells and monocytes of idiopathic inflammatory myopathy patients with different myositis-specific autoantibodies. Front Immunol. 2023, 14:1169057. 10.3389\/fimmu.2023.1169057","journal-title":"Front Immunol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1151695","article-title":"Type I interferon score is associated with the severity and poor prognosis in anti-MDA5 antibody-positive dermatomyositis patients","volume":"14","author":"Qian J","year":"2023","unstructured":"Qian J, Li R, Chen Z, Cao Z, Lu L, Fu Q. Type I interferon score is associated with the severity and poor prognosis in anti-MDA5 antibody-positive dermatomyositis patients. Front Immunol. 2023, 14:1151695. 10.3389\/fimmu.2023.1151695","journal-title":"Front Immunol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1328547","article-title":"Transcriptome analysis of skeletal muscle in dermatomyositis, polymyositis, and dysferlinopathy, using a bioinformatics approach","volume":"14","author":"Jeong HN","year":"2023","unstructured":"Jeong HN, Lee TG, Park HJ, Yang Y, Oh SH, Kang SW, Choi YC. Transcriptome analysis of skeletal muscle in dermatomyositis, polymyositis, and dysferlinopathy, using a bioinformatics approach. Front Neurol. 2023, 14:1328547. 10.3389\/fneur.2023.1328547","journal-title":"Front Neurol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0260511","article-title":"Ten genes are considered as potential biomarkers for the diagnosis of dermatomyositis","volume":"16","author":"Xiao L","year":"2021","unstructured":"Xiao L, Xiao W, Lin S. Ten genes are considered as potential biomarkers for the diagnosis of dermatomyositis. PLoS One. 2021, 16:e0260511. 10.1371\/journal.pone.0260511","journal-title":"PLoS One"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/nan.12519","article-title":"Diagnostic potential of sarcoplasmic myxovirus resistance protein A expression in subsets of dermatomyositis","volume":"45","author":"Uruha A","year":"2019","unstructured":"Uruha A, Allenbach Y, Charuel JL, et al.. Diagnostic potential of sarcoplasmic myxovirus resistance protein A expression in subsets of dermatomyositis. Neuropathol Appl Neurobiol. 2019, 45:513-22. 10.1111\/nan.12519","journal-title":"Neuropathol Appl Neurobiol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003568","article-title":"Sarcoplasmic MxA expression: a valuable marker of dermatomyositis","volume":"88","author":"Uruha A","year":"2017","unstructured":"Uruha A, Nishikawa A, Tsuburaya RS, et al.. Sarcoplasmic MxA expression: a valuable marker of dermatomyositis. Neurology. 2017, 88:493-500. 10.1212\/WNL.0000000000003568","journal-title":"Neurology"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1429817","article-title":"Identification and validation of interferon-stimulated gene 15 as a biomarker for dermatomyositis by integrated bioinformatics analysis and machine learning","volume":"15","author":"Wang X","year":"2024","unstructured":"Wang X, Hu H, Yan G, Zheng B, Luo J, Fan J. Identification and validation of interferon-stimulated gene 15 as a biomarker for dermatomyositis by integrated bioinformatics analysis and machine learning. Front Immunol. 2024, 15:1429817. 10.3389\/fimmu.2024.1429817","journal-title":"Front Immunol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S433239","article-title":"Sarcoplasmic myxovirus resistance protein A: a study of expression in idiopathic inflammatory myopathy","volume":"16","author":"Waisayarat J","year":"2023","unstructured":"Waisayarat J, Wongsuwan P, Tuntiseranee K, Waisayarat P, Dejthevaporn C, Khongkhatithum C, Soponkanaporn S. Sarcoplasmic myxovirus resistance protein A: a study of expression in idiopathic inflammatory myopathy. J Inflamm Res. 2023, 16:5417-26. 10.2147\/JIR.S433239","journal-title":"J Inflamm Res"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez078","article-title":"MxA is a clinically applicable biomarker for type I interferon activation in systemic lupus erythematosus and systemic sclerosis","volume":"58","author":"Huijser E","year":"2019","unstructured":"Huijser E, van Helden-Meeuwsen CG, Groot N, et al.. MxA is a clinically applicable biomarker for type I interferon activation in systemic lupus erythematosus and systemic sclerosis. Rheumatology (Oxford). 2019, 58:1302-3. 10.1093\/rheumatology\/kez078","journal-title":"Rheumatology (Oxford)"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1002\/art.27224","article-title":"Systemic sclerosis and lupus: points in an interferon-mediated continuum","volume":"62","author":"Assassi S","year":"2010","unstructured":"Assassi S, Mayes MD, Arnett FC, et al.. Systemic sclerosis and lupus: points in an interferon-mediated continuum. Arthritis Rheum. 2010, 62:589-98. 10.1002\/art.27224","journal-title":"Arthritis Rheum"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000855","article-title":"Where are we moving in the classification of idiopathic inflammatory myopathies?","volume":"33","author":"Tanboon J","year":"2020","unstructured":"Tanboon J, Uruha A, Stenzel W, Nishino I. Where are we moving in the classification of idiopathic inflammatory myopathies?. Curr Opin Neurol. 2020, 33:590-603. 10.1097\/WCO.0000000000000855","journal-title":"Curr Opin Neurol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani M","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016, 5:210. 10.1186\/s13643-016-0384-4","journal-title":"Syst Rev"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11113021","article-title":"Expression of inflammatory markers in the muscles of patients with idiopathic inflammatory myopathy according to the presence of interstitial lung disease","volume":"11","author":"Lee JS","year":"2022","unstructured":"Lee JS, Ghang B, Choi W, et al.. Expression of inflammatory markers in the muscles of patients with idiopathic inflammatory myopathy according to the presence of interstitial lung disease. J Clin Med. 2022, 11:3021. 10.3390\/jcm11113021","journal-title":"J Clin Med"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-025-03532-9","article-title":"Nailfold videocapillaroscopy findings are associated with IIM subtypes and IFN activation","volume":"27","author":"Tang M","year":"2025","unstructured":"Tang M, Shi J, Pang Y, et al.. Nailfold videocapillaroscopy findings are associated with IIM subtypes and IFN activation. Arthritis Res Ther. 2025, 27:62. 10.1186\/s13075-025-03532-9","journal-title":"Arthritis Res Ther"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.4132\/jptm.2024.05.02","article-title":"Immunohistochemical expression in idiopathic inflammatory myopathies at a single center in Vietnam","volume":"58","author":"Ngo DQ","year":"2024","unstructured":"Ngo DQ, Le ST, Phan KH, et al.. Immunohistochemical expression in idiopathic inflammatory myopathies at a single center in Vietnam. J Pathol Transl Med. 2024, 58:174-81. 10.4132\/jptm.2024.05.02","journal-title":"J Pathol Transl Med"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1038\/srep43201","article-title":"Classification of idiopathic interstitial pneumonias using anti-myxovirus resistance-protein 1 autoantibody","volume":"7","author":"Hamano Y","year":"2017","unstructured":"Hamano Y, Kida H, Ihara S, et al.. Classification of idiopathic interstitial pneumonias using anti-myxovirus resistance-protein 1 autoantibody. Sci Rep. 2017, 7:43201. 10.1038\/srep43201","journal-title":"Sci Rep"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e16512","article-title":"The impact that myocarditis for post-acute COVID-19 syndrome may be dermatomyositis-like myocarditis: a case report","volume":"9","author":"Kinoshita H","year":"2023","unstructured":"Kinoshita H, Kurashige T, Fukuda T, et al.. The impact that myocarditis for post-acute COVID-19 syndrome may be dermatomyositis-like myocarditis: a case report. Heliyon. 2023, 9:e16512. 10.1016\/j.heliyon.2023.e16512","journal-title":"Heliyon"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-024-03364-z","article-title":"Expression of CD163 and major histocompatibility complex class I as diagnostic markers for idiopathic inflammatory myopathies","volume":"26","author":"Ghang B","year":"2024","unstructured":"Ghang B, Nam SH, Choi W, et al.. Expression of CD163 and major histocompatibility complex class I as diagnostic markers for idiopathic inflammatory myopathies. Arthritis Res Ther. 2024, 26:144. 10.1186\/s13075-024-03364-z","journal-title":"Arthritis Res Ther"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.628128","article-title":"Aberrantly expressed galectin-9 is involved in the immunopathogenesis of anti-MDA5-positive dermatomyositis-associated interstitial lung disease","volume":"9","author":"Liang L","year":"2021","unstructured":"Liang L, Zhang YM, Shen YW, et al.. Aberrantly expressed galectin-9 is involved in the immunopathogenesis of anti-MDA5-positive dermatomyositis-associated interstitial lung disease. Front Cell Dev Biol. 2021, 9:628128. 10.3389\/fcell.2021.628128","journal-title":"Front Cell Dev Biol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab601","article-title":"Siglec-1 expression on monocytes is associated with the interferon signature in juvenile dermatomyositis and can predict treatment response","volume":"61","author":"Lerkvaleekul B","year":"2022","unstructured":"Lerkvaleekul B, Veldkamp SR, van der Wal MM, et al.. Siglec-1 expression on monocytes is associated with the interferon signature in juvenile dermatomyositis and can predict treatment response. Rheumatology (Oxford). 2022, 61:2144-55. 10.1093\/rheumatology\/keab601","journal-title":"Rheumatology (Oxford)"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1111\/neup.12816","article-title":"Pathological features of inflammatory myopathy as a manifestation of chronic graft-versus-host disease after allogeneic bone marrow transplantation","volume":"42","author":"Shiota T","year":"2022","unstructured":"Shiota T, Eura N, Hasegawa A, Kiriyama T, Sugie K. Pathological features of inflammatory myopathy as a manifestation of chronic graft-versus-host disease after allogeneic bone marrow transplantation. Neuropathology. 2022, 42:309-14. 10.1111\/neup.12816","journal-title":"Neuropathology"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awy105","article-title":"JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis","volume":"141","author":"Ladislau L","year":"2018","unstructured":"Ladislau L, Su\u00e1rez-Calvet X, Toquet S, et al.. JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis. Brain. 2018, 141:1609-21. 10.1093\/brain\/awy105","journal-title":"Brain"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/440175-evaluating-the-diagnostic-potential-of-myxovirus-resistance-protein-1-mx1-and-myxovirus-resistance-protein-2-mx2-as-biomarkers-in-idiopathic-inflammatory-myopathies","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T16:22:54Z","timestamp":1769703774000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/440175-evaluating-the-diagnostic-potential-of-myxovirus-resistance-protein-1-mx1-and-myxovirus-resistance-protein-2-mx2-as-biomarkers-in-idiopathic-inflammatory-myopathies"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":41,"URL":"https:\/\/doi.org\/10.7759\/cureus.102565","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,29]]}}}